GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?

GSK (GSK) stock has declined 20.2% in the past three months compared with a decrease of 12.3% for the industry. The stock has also underperformed the sector and the S&P 500 index, as seen in the chart below. The stock is also trading below its 200 and 50-day moving averages.GSK Stock Underperforms Industry, Sector and S&PImage Source: Zacks Investment ResearchGSK enjoys a strong position in HIV and Vaccines therapeutic areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug developm ...